These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25877064)

  • 1. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.
    Phillips JT; Hutchinson M; Fox R; Gold R; Havrdova E
    Mult Scler Relat Disord; 2014 Jul; 3(4):513-9. PubMed ID: 25877064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
    O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
    Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
    Sheikh SI; Nestorov I; Russell H; O'Gorman J; Huang R; Milne GL; Scannevin RH; Novas M; Dawson KT
    Clin Ther; 2013 Oct; 35(10):1582-1594.e9. PubMed ID: 24139424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl Fumarate: A Review of Efficacy and Practical Management Strategies for Common Adverse Events in Patients with Multiple Sclerosis.
    Phillips JT; Agrella S; Fox RJ
    Int J MS Care; 2017; 19(2):74-83. PubMed ID: 32607065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
    Phillips JT; Selmaj K; Gold R; Fox RJ; Havrdova E; Giovannoni G; Abourjaily H; Pace A; Novas M; Hotermans C; Viglietta V; Meltzer L
    Int J MS Care; 2015; 17(5):236-43. PubMed ID: 26472945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.
    Theodore Phillips J; Erwin AA; Agrella S; Kremenchutzky M; Kramer JF; Darkes MJ; Kendter J; Abourjaily H; Rana J; Fox RJ
    Neurol Ther; 2015 Dec; 4(2):137-46. PubMed ID: 26525536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).
    Gold R; Schlegel E; Elias-Hamp B; Albert C; Schmidt S; Tackenberg B; Xiao J; Schaak T; Salmen HC
    Ther Adv Neurol Disord; 2018; 11():1756286418768775. PubMed ID: 29707040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.
    Mayer L; Fink MK; Sammarco C; Laing L
    Drug Saf; 2018 Apr; 41(4):347-356. PubMed ID: 29218681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach.
    Campbell TL; Lefaux BJ; Mayer LL; Namey M; Riemer G; Robles-Sanchez MA; White S; Edwards M; Minor C
    J Neurosci Nurs; 2020 Apr; 52(2):72-77. PubMed ID: 32068560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
    Fox EJ; Vasquez A; Grainger W; Ma TS; von Hehn C; Walsh J; Li J; Zambrano J
    Int J MS Care; 2016; 18(1):9-18. PubMed ID: 26917993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.
    Min J; Cohan S; Alvarez E; Sloane J; Phillips JT; van der Walt A; Koulinska I; Fang F; Miller C; Chan A
    Neurol Ther; 2019 Jun; 8(1):109-119. PubMed ID: 30706431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A; Wray S; Gold R; Singer BA; Jasinska E; Ziemssen T; de Seze J; Repovic P; Chen H; Hanna J; Messer J; Miller C; Naismith RT
    Ther Adv Neurol Disord; 2021; 14():1756286421993999. PubMed ID: 33796143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
    J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Allan M; Grant L
    Neurol Ther; 2020 Jun; 9(1):85-92. PubMed ID: 31834566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis.
    Liang G; Chai J; Ng HS; Tremlett H
    Mult Scler Relat Disord; 2020 Nov; 46():102566. PubMed ID: 33296968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
    Liseno J; Lager B; Miller C; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2021 Jun; 10(1):349-360. PubMed ID: 33846959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.